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The SIEFED (“Speciﬁc Immunological Extraction Followed by Enzymatic Detection”) method already
developed for the speciﬁc detection of the activity of equine myeloperoxidase (MPO) was adapted for the
speciﬁc measurement of active human MPO in biological ﬂuids or tissue extracts. The method consists of
the extraction of MPO from aqueous solutions by immobilized anti-MPO antibodies followed by a wash-
ing (to eliminate the extractionmediumand the biological ﬂuidwith their possible interferingmolecules)





H2O2 and nitrite ions as reaction enhancer. The SIEFED was applied to study active MPO in human biolog-
ical ﬂuids (plasma, bronchoalveolar lavage ﬂuid and supernatant from carotids extracts). The SIEFED for
humanMPOhas a sensitivity limit of 0.080mU/mL and showedgoodprecisionwith intra- and inter-assay
coefﬁcients of variation below 10 and 20% respectively within a broad range of MPO activities establish




MPO in complex ﬂuids an
healthy volunteers and p
. Introduction
Neutrophil myeloperoxidase (MPO) is involved in the intracel-
ular bacterial destruction by producing potent oxidant molecules,
ainly hypochlorous acid (HOCl) [1,2]. MPO is released in the
xtracellular milieu by dying or highly stimulated neutrophils in
athological conditions of acute and chronic inﬂammations [2–6].
n these conditions, MPO is able to exert a deleterious oxidant
ctivity on neighbouring cells and tissues, and a therapeutic tar-
et should be to modulate its activity. Increased blood levels of
PO are now considered as markers of neutrophil activation and
egranulation [7,8] and are measured by immunological methods
ELISAorRIA),whichquantify the total concentrationof theenzyme
9,10] without reﬂecting its true enzymatic activity. The activity of
PO is currently measured by the direct addition in the medium
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ts especially in case of chronic or acute inﬂammatory diseases.
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of H2O2 and a chromogenic or ﬂuorogenic substrate as electron
donors [11–13]. The oxidation of these electron donors is moni-
tored by spectrophotometry or ﬂuorimetry as a probe of the MPO
activity [14,15]. Although thesemethods are suitable formeasuring
the activity of MPO in vitro in simple mixtures [13], they lack sensi-
tivity, are cumbersome for cohort measurements and are not easily
applicable to complex biological samples such as blood, plasma,
or tissues, because of interferences with components endowed
with peroxidasic activity (e.g. haemoglobin) [16,17], proteins (e.g.
albumin, lipoproteins, ceruloplasmin) [18,19], reducing agents (e.g.
ascorbic acid, glutathione) [16]. The physicochemical character-
istics (pH, viscosity, etc.), the redox status or the colour of the
biological ﬂuids also interfere with the reading of the colorimetric
or ﬂuorescence response.
We designed a new technique, the SIEFED (for “Speciﬁc
Immunological Extraction Followed by Enzymatic Detection”) to
measure the activity of an enzyme in biological ﬂuids, and ﬁrstly
developed it for equine MPO [20]. The major advantage of the
SIEFED technique is its rapidity and an easy extraction of MPO out
of the sample or reaction mixture by speciﬁc immobilized anti-

























































p24 T. Franck et al. / Ta
tep that eliminates the solution and its potential interfering capac-
ty, before starting the detection of MPO enzymatic activity. In
uman, increasing evidence indicated that MPO plays important
oles in the initiation and progression of arthritis, carcinogenesis,
ulmonary, kidney, neurodegenerative, inﬂammatory bowel and
specially cardiovascular diseases in which the enzyme is taken
s an inﬂammatory marker and a prognostic agent [6]. In these
iseases, an important clinical aspect is to know the active part
f MPO, which is the real witness of the oxidant potential of the
nzyme. We describe here the development and optimization of
he SIEFED technique for the speciﬁc detection of the enzymatically
ctive humanMPO in complexmedia [plasma, bronchoalveolar ﬂu-
ds (BALs)] and tissue extracts (carotids). The SIEFED technique is
ased on the immunological capture of the antigen by antibod-
es. An interesting point of this study was to compare the active
PO contentmeasured by SIEFEDwith the totalMPO contentmea-




Analytical grade phosphate salts, sodium and potassium chlo-
ides, sodium hydroxide, sodium acetate, H2O2 (30%, w/v), ethanol
nd Tween 20 and human myeloperoxidase (Calbiochem) were
urchased from Merck (VWR International, Leuven, Belgium).
ovine serum albumin (BSA) and sodium nitrite were purchased
romSigma–Aldrich (Bornem, Belgium). 96-Wellsmicrotiter plates
Combiplate 8 EB) were from Thermo Scientiﬁc (Breda, The
etherlands). The ﬂuorogenic substrate, Amplex Red (10-acetyl-
,7-dihydroxyphenoxazine),waspurchased fromMolecularProbes
Invitrogen) (Merelbeke, Belgium).
.2. Puriﬁcation of human MPO and rabbit anti-human MPO
olyclonal antibodies
MPO was puriﬁed from human neutrophils by detergent
nhanced extraction followed by two steps of chromatography,
nd antisera were obtained by rabbit immunization against the
ure human MPO emulsiﬁed with complete Freud adjuvant as pre-
iously described [9,21]. Polyclonal antibody (IgG), puriﬁed from
abbit antisera by afﬁnity chromatography on Protein A sepharose
GE Healthcare, The Netherlands), was characterized for its speci-
city and stability and ﬁrstly used to develop a radioimmunoassay
or total MPO assay in human plasma [9].
.3. Methodology of the SIEFED technique
Three buffers were used. The coating buffer was 20mM K and
a phosphates (pH 7.4), 137mM NaCl and 2.7mM KCl. The block-
ng buffer was obtained by addition of 5 g/L BSA to the coating
uffer. The diluting buffer was the blocking buffer added with
.1% Tween 20. The washing solution was 154mM NaCl with
.1% Tween 20. Microtitration wells were coated overnight, at
◦C with 100L/well of serial dilutions of a rabbit IgG solution
62.5–500ng/well) diluted with the coating buffer to determine
he optimal IgG concentration to be used in the SIEFED assay.
fter removing the coating solution, the blocking bufferwas added,
he plates were incubated for 150min at room temperature and
ashed three times. Serial dilutions of a standard MPO solutionpure humanMPO) or unknown sampleswere added (100L/well)
nd incubated for 1 or 2h either at 22 ◦C or at 37 ◦C or for 20h
t 4 ◦C. After three washings, the peroxidasic activity of MPO was
etected by adding 100L of a 40M Amplex Red solution freshly
repared in phosphate buffer (50mM) at pH 7.5 and added with0 (2009) 723–729
10M H2O2 and 10mM nitrite. After incubation in the dark-
ness (30min, 37 ◦C), the ﬂuorescence was read with a Fluoroscan
Ascent (Thermo Scientiﬁc) with excitation and emission wave-
lengths set at 544 and 590nm, respectively. Controls (blank) were
performed with the dilution buffer. The ﬂuorescence value was
directly proportional to the quantity of active MPO present in the
sample.
2.4. Validation of the SIEFED technique
The stability of the reference human MPO (from Calbiochem)
was tested after its dilution in phosphate buffer saline (PBS) or PBS
addedwith 5g/L BSA and0.1% Tween20 (dilution buffer) and either
incubated for 2h at 37 ◦C or submitted to several freezing–thawing
cycles.
The cross-reactivity of the anti-MPO antibodies with albumin,
haemoglobin, elastase or eosinophil peroxidase was measured as
previously described [9]. The detection limit was deﬁned as the
lowest active MPO concentration (mean value± SD) that was sta-
tistically different from the value obtained with buffer alone. The
standard curve was calculated and plotted point to point by using
the Ascent Software for Multiscan Ascent (Thermo Labsystems).
The precision and reproducibility were estimated by the coefﬁ-
cients of variation (CV) within or between assays calculated for
several determinations of the same sample in the same assay or
in different assays performed on different days. Accuracy was esti-
mated by the recovery of known amounts of puriﬁed MPO added
to the samples (plasma, BALs and carotid extracts).
To assure that the SIEFED technique could be reproduced with
other anti-MPO antibodies, the immunoreactivity of our antibody
was compared with that of the primary MPO-antibody (polyclonal
antibody from rabbit) used in the MPO-ELISA kit (ELIZEN MPO)
purchased from the Zentech company (Belgium).
2.5. Sampling technique
To test the stability of the neutrophils in blood after sampling,
blood was drawn from ﬁve healthy donors without anticoag-
ulant and on three anticoagulants with centrifugation (10min,
22 ◦C, 1000× g) 1 or 3h after sampling. The anticoagulants were
EDTA (1.8mg/mL blood, in 3.5mL vacutainer tubes; Venosafe,
Terumo, Belgium), lithium heparin (15 IU/mL blood), or citrate
(3.2% Na-citrate solution). Blood in plain tubes was allowed to
clot (3h) at room temperature (22 ◦C) before serum collection.
For all the other studies with healthy and pathological subjects,
venousperipheral blood sampleswereobtained invacutainer tubes
on EDTA (1.8mg/mL blood), and centrifuged within 30min after
drawing.
Bronchoalveolar lavages (BALs) were performed in intensive
care patients for therapeutic purpose (bacterial agent determina-
tion) via the endotracheal tube, with four aliquots of 50mL warm
sterile 0.9% NaCl solution as previously described [22]. The ﬁrst
aliquotwas discarded and the secondused for bacterial studies. The
aspirated liquids of the third and the fourth aliquots were strained
through sterile gauze and centrifuged (10min, 4 ◦C, 300× g); the
supernatant was used for SIEFED assay.
Carotid atherosclerotic plaques were collected during surgery
for carotid thrombo-endatherectomy and rinsed with 0.9% NaCl
solution before their freezing at −20 ◦C. After thawing, the carotid
plaques were homogenised on ice in 20–25mL of cold 10mM Tris-
buffer, pH7.4. The extractwas centrifuged (20min, 4 ◦C, 17,000× g)
and the supernatant was used for SIEFED assay.
Plasma samples, supernatants from BALs and carotid extracts
were freshly used or kept frozen in small aliquots at −20 ◦C. Imme-
diately before the SIEFED assay, samples were thawed and diluted
with the diluting buffer before loading into the wells.
T. Franck et al. / Talanta 80 (2009) 723–729 725

























M0 after an incubation period of 2h at 37 ◦C or after several freezing–thawing (FT)
ycles. The test performeddirectly afterMPOdilutionwas taken as 100%.Mean± SD,
= 3, ANOVA *p<0.05 versus initial solubilization in PBS+BSA+Tween 20; #p<0.05
ersus initial solubilization in PBS.
Optimal dilutionwasdeterminedby testing serial dilutions (1:1,
:2.5, 1:5, 1:10, 1:20, 1:40, 1:80) of the samples in the dilution
uffer.
.6. Total MPO assay by a sandwich ELISA
To compare active MPO to the total content of the enzyme,
otal (active and non-active) MPO was measured with a sandwich
uman myeloperoxidase ELISA kit (ELIZEN MPO, Zentech SA, Bel-
ium). Before the ELISA, plasma samples, and carotid extracts were
iluted 20 times and BAL samples 50 times with the diluting buffer
urnished by the ELISA kit.
.7. Statistical analysis
SigmaStat 3.5 software (Systat, San Jose, CA) was used for the
nalysis. Data are presented as the mean± SD and were evaluated
y a one-way ANOVA.
. Results
.1. Stabilization of the reference human MPO
According to the supplier (Calbiochem), human MPO speciﬁc
ctivity ranged from 180 to 220U/mg proteins: we took the mean
alue, 200U/mg proteins, asMPO speciﬁc activity. Fig. 1 shows that
POdiluted inPBSwasnot stable: the enzyme lost 51.4±3.7%of its
ctivity after 2h at 37 ◦C and 89.0±0.5% after three freezing thaw-
ng cycles. In PBS with 5g/L BSA and 0.1% Tween 20, MPO remained
able 1
tandard curve values for the measurement of active human MPO by the SIEFED techniqu









ean± SD, n=5. The detection limit of the test was 0.080mU/mL.Fig. 2. Standard curve for the measurement of the activity of human MPO by the
SIEFED technique (mean± SD, n=5).
stable, with only a slight loss of activity of 8.8±1.1 and 7.3±2.2%
respectively after 2h at 37 ◦C or three freezing thawing cycles.
3.2. Calibration curve and detection limit of the SIEFED technique
The standard curve was obtained by plotting the ﬂuorescence
values as a function of the known activity of the reference MPO,
from 0.156 to 10mU/mL (Fig. 2). Table 1 shows the ﬂuores-
cence data measured for a typical active MPO reference curve
(mU/mL) with the corresponding reference concentrations of the
pure human MPO in ng/mL. The intra-assay CVs did not exceed 8%.
The detection limit of the test (0.080mU/mL) was determined as
the lowest activeMPOconcentration (meanvalue± SD) statistically
different from the value obtained with buffer alone.
3.3. SIEFED method for MPO measurement in biological samples
Based on the detection limit and the slope of the standard curve,
we chose 250ng per well (or 2.5g/mL) as the optimal concentra-
tion of the coating antibody. After blocking andwashing, the coated
plates couldbe storedat 4 ◦Cunderdry conditions for up to4weeks.
Thebinding of puriﬁedMPO to the coated antibodies increaseswith
time and is similar at 37 ◦C and room temperature (RT) (Fig. 3). The
activity of the samplesmeasured after the incubation at RT are gen-
erally lower than after the incubation at 37 ◦C but, interestingly, the
activity obtained after an overnight incubation at 4 ◦C or after 1 or
2h incubation at 37 ◦C are similar (CV<10%) (results not shown).
The incubation at 4 ◦C does not disturb the activity of MPO and
its binding to the antibody. The rapidity of the test being a priority
◦factor, a 2h incubation time at 37 C was chosen for further studies.
As previously described [20], to reach a high sensitivity of
the SIEFED technique for its application to biological samples, we
used as peroxidase substrate, the Amplex Red molecule, which is
transformed into the ﬂuorescent resoruﬁn upon its peroxidase-
e.
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Table 2
Effect of the delay between blood collection and centrifugation on the activity of MPO measured by SIEFED in anticoagulated plasma and serum.
Collecting tube Time between blood collection
and centrifugation (h)
Mean MPO activity (mU/mL) SD (mU/mL) CV (%)
Citrate 1 1.4 0.3 23.2
3 2.5 1.0 39.0
EDTA 1 1.9 0.2 11.7
3 3.4 0.3 7.9



































matic MPO was active in the healthy donors. The values of active
and total MPO in ﬁve pathological plasmas, ranged from 80.5 to
210.7ng/mL for active MPO and from 87.1 to 235.4ng/mL for total3
Dry (serum) 3
ean± SD of ﬁve healthy donors, n=5.
atalyzed oxidation by H2O2 [23]. The optimal working conditions
o measure the activity of MPO were reached with a freshly pre-
ared 40M Amplex Red solution and 10M H2O2. The addition
f 10mM sodium nitrite (NaNO2) in the reaction mixture increased
–5-folds the sensitivity of the SIEFED [20].
.4. Sampling conditions: effects of the anticoagulant and the
elay in blood centrifugation
When centrifugation was done 1h after blood sampling, the
owest mean MPO activity was observed for blood drawn on cit-
ate and the highest one for blood drawn on Li-heparin (Table 2).
fter a delay of 3h before centrifugation, the MPO activity val-
es increased 1.8 times for EDTA and citrate and 2.1 times for
i-heparin. Interestingly, the lowest CVs, both after 1 and 3h before
lood centrifugation, were obtained for the EDTA plasmas what
uggested that the neutrophils remained stable with time. For cit-
ate and Li-heparin samples, the high CVs were unacceptable. A
igh mean value of MPO activity was observed for serum (Table 2).
n the basis of these results, it was decided to use preferably EDTA
nticoagulated blood for all the other studies; citrated samples
btained after blood centrifugation within 1h can also be used, but
e excluded the serum samples.
.5. Application of the SIEFED technique to biological samples
The dilution of the sample improved the MPO activity till the
ilution1:10, undoubtedly by improving the binding betweenMPO
nd the primary antibody (Fig. 4). At higher dilutions, themeasured
alues were stabilized and reached a plateau for most samples at
he dilution 1:20 and for some samples at the dilution 1:40. But
t this dilution, the limit of sensitivity is reached for samples with
ow content of active MPO. Linearity of the assay was determined
y evaluating dilutional parallelism. Percentages of recovery calcu-
ated from observed-to-expected values for two plasmas, two BALs
ig. 3. Effects of incubation time and temperature on the MPO binding to its anti-
odies (mean± SD, n=3)..3 2.1 32.4
.9 5.1 25.8
and two carotid extracts at two dilution factors (1:10 and 1:20)
ranged from 94.1 to 130.0% (mean± SD: 113.4±12.2%; Table 3).
The accuracy of the assay was evaluated by determining the
spiking recovery in twoplasmas, twoBALs and twocarotid extracts.
Percentages of recovery for seven spiking concentrations of active
MPO added to the samples ranged from 72.6 to 113.1% (mean± SD:
93.5±9.2%; Table 4). A lack of recovery above 20%was observed for
the highest active MPO concentrations (2.5 and 5mU/mL) added to
the plasma samples, but not to BALs and carotid extracts.
The intra-assay precision of the SIEFED technique estimated by
repeated measurements within the same run on three different
types of biological ﬂuids with MPO activities ranging from 2.6 to
473.0mU/mL showed CVs that did not exceed 10%. The mean CV
value for all the samples (n=45) was 3.8±2.7% (Table 5).
Inter-assay precision was estimated by duplicate or triplicate
assays of the biological ﬂuids performed in different runs over a
period of 4, 3 or 2 days. The MPO activities ranged from 1.8 to
118.1mU/mL and the CVs did not exceed 20%. The mean CV value
for all the samples (n=49) was 10.2±4.8% (Table 5).
In the plasma of 19 healthy donors, the total and active MPO
contents were measured by ELISA (ELIZEN MPO, Zentech, Belgium)
and by SIEFED respectively after checking that the primary anti-
body used in the kit had a similar response for the capture of
active MPO than our antibody, and by diluting the samples in the
same manner for the ELISA and the SIEFED. The mean total MPO
value was 42.0±15.0ng/mL, while the mean active MPO value was
15.1±5.2ng/mL corresponding to 3.0±1.0mU/mL (Table 6). The
active/total MPO ratio indicates that about 40±9% of total plas-MPO, were higher than the mean value obtained in healthy donors
Fig. 4. Curves obtained with serial dilutions of plasma, carotid extracts and BALs
(mean± SD, n=5).
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Table 3
Active MPO values measured by SIEFED for dilutional parallelism of plasma, carotid extracts and BALs (mean± SD, n=3).
Samples Dilution factor MPO observed value (mU/mL) MPO expected value (mU/mL) Recovery (%)
Plasma 1 1:10 0.53
1:20 0.30 0.27 111.1
Plasma 2 1:10 1.71
1:20 1.04 0.85 122.3
Carotid 1 1:10 9.04
1:20 5.88 4.52 130.0
Carotid 2 1:10 0.42
1:20 0.23 0.21 110.0
BAL 1 1:10 10.23
1:20 5.77 5.12 112.6
BAL 2 1:10 0.34
1:20 0.16 0.17 94.1
Table 4
Recovery of spiked active human MPO measured by SIEFED in plasma, carotid extracts, and BALs.
Samples Initial active MPO (mU/mL) Added active MPO (mU/mL) MPO expected (mU/mL) MPO observed (mU/mL) Recovery (%)
Plasma 1 (dilution 1:20) 0.843 0.078 0.92 0.90 97.8
0.156 1.00 0.96 96.0
0.312 1.16 1.18 101.7
0.625 1.47 1.38 93.9
1.25 2.09 1.86 89.0
2.5 3.34 2.79 83.5
5 5.84 4.33 74.1
Plasma 2 (dilution 1:10) 2.73 0.078 2.81 2.80 99.6
0.156 2.89 2.82 97.6
0.312 3.04 2.87 94.4
0.625 3.36 3.02 89.9
1.25 3.98 3.41 85.7
2.5 5.23 4.12 78.8
5 7.73 5.61 72.6
Carotid 1 (dilution 1:20) 5.8 0.078 5.84 6.24 106.9
0.156 5.91 6.21 105.1
0.312 6.07 6.22 102.5
0.625 6.38 6.58 103.1
1.25 7.01 6.82 97.3
2.5 8.26 7.95 96.3
5 10.76 9.73 90.4
Carotid 2 (dilution 1:10) 0.53 0.078 0.61 0.69 113.1
0.156 0.69 0.69 100.0
0.312 0.84 0.86 102.4
0.625 1.16 1.31 112.9
1.25 1.78 1.84 103.4
2.5 3.03 2.94 97.0
5 5.53 5.11 92.4
BAL 1 (dilution 1:20) 0.53 0.078 0.61 0.56 91.8
0.156 0.69 0.66 95.7
0.312 0.84 0.80 95.2
0.625 1.16 1.02 87.9
1.25 1.78 1.47 82.6
2.5 3.03 2.42 79.9
5 5.53 4.48 81.0
BAL 2 (dilution 1:10) 1.565 0.078 1.64 1.55 94.2
0.156 1.72 1.56 90.8
0.312 1.88 1.75 93.5
0.625 2.19 2.01 91.6








Table 6). The active/totalMPO ratiowas also higher than in healthy
ontrols,witha range from0.5 to0.9 (Table6). In theﬁvecarotidand
hree BAL samples, the ratio of active versus totalMPO showed that
he active part of the enzyme varied from 20 to 90% of total MPO
mount (Table 6), but no comparison was possible with healthy
arotid and BAL samples.4.07 3.50 86.1
6.57 6.00 91.4
4. DiscussionOwing to our experience with equine MPO [20] and RIA assay of
human MPO [21], we developed a SIEFED technique for the speciﬁc
and rapid measurement of the enzymatically active form of human
MPO in complex biological samples. This technique has ﬁve inter-
728 T. Franck et al. / Talanta 8
Table 5
Intra- and inter-assay reproducibility of the SIEFED technique for active MPO mea-
surements in human plasma, carotid extracts and BALs.
Samples na Mean MPO activity
(mU/mL)
SD (mU/mL) CV (%)
Intra-assay
Plasma 1 4 16.0 0.2 1.3
Plasma 2 4 9.5 0.1 1.1
Plasma 3 3 6.3 0.0 0.6
Plasma 4 3 16.3 0.5 3.1
Plasma 5 2 5.9 0.3 5.1
Plasma 6 2 15.3 0.4 2.6
Carotid 1 4 119.5 11.9 10.0
Carotid 2 4 167.3 12.0 7.2
Carotid 3 3 4.2 0.1 2.4
Carotid 4 2 61.7 1.7 2.8
Carotid 5 2 473.0 26.0 5.5
BAL 1 4 4.3 0.1 2.3
BAL 2 4 30.9 2.2 7.1
BAL 3 2 17.6 0.4 2.3
BAL 4 2 2.6 0.1 3.8
Samples nb Mean MPO activity
(mU/mL)
SD (mU/mL) CV (%)
Inter-assay
Plasma 7 4 2.9 0.5 17.2
Plasma 8 4 15.5 0.5 3.2
Plasma 9 3 10.7 1.1 10.2
Plasma 10 3 24.4 2.4 9.8
Plasma 11 2 6.9 0.6 8.7
Plasma 12 2 19.8 3.2 16.1
Carotid 6 4 1.8 0.3 16.7
Carotid 7 4 54.7 2.4 4.3
Carotid 8 3 16.8 2.3 13.7
Carotid 9 3 88.4 9.5 10.7
Carotid 10 2 118.1 4.5 3.8
Carotid 12 2 4.4 0.4 9.1
BAL 5 4 5.5 0.9 16.3
BAL 6 4 31.0 2.8 9.0
BAL 7 3 29.0 2.9 3.4
BAL 8 2 50.8 5.6 11.0








The study of the blood sampling conditions revealed that con-
T
C
ca Number of sample measurement during the same assay.
b Number of assays with the sample measured in duplicate or triplicate in each
ssay.
sting characteristics: (i) the easy immuno-capture of MPO out of a
iological sample (or a reaction mixture containing MPO) without
ny preparation of the sample (no partial puriﬁcation or precip-
tation of the enzyme), which is simply diluted, loaded into the
ntibody-coated wells and discarded after the incubation period
uring which MPO binding has occurred, (ii) the washing after the
able 6
oncentration (ng/mL) of active and total MPO measured by SIEFED and ELISA and activ
arotid extracts and 3 BALs of pathological subjects.
Active MPO (mU/mL) A
Mean plasmatic value for 19 healthy donors 3.0±1.0
Plasma 1 19.8
Plasma 2 26.1 1
Plasma 3 42.1 2
Plasma 4 23.1 1
Plasma 5 16.1
Carotid 1 4.6





BAL 2 21.9 1
BAL 3 2.60 (2009) 723–729
immuno-capture of MPO to eliminate the sample with its com-
pounds potentially able to interfere with the enzymatic detection
step, (iii) the speciﬁcity since the speciﬁc antibodies will only cap-
ture human MPO so that the detection system will disclose only
the MPO activity, (iv) the high sensitivity of the test reached by the
combined used of Amplex Red, a stable ﬂuorogenic substrate for
detectionof peroxidases [12], andnitrite as an enhancer of the reac-
tion, (v) themeasurementof theactivityby referring toa calibration
curve made with pure human MPO.
As previously described, the success of the SIEFED technique
depends on a good compromise between a strong binding of MPO
and a low inhibition of its activity by the antibodies [20]. We
obtained the best conditions to bind active MPO by coating the
wells with 250ng of rabbit anti-MPO IgG. The use of a polyclonal
antibody increased the possibilities to capture MPO by different
epitopes, but also the risk to inhibit the enzyme as observed in dif-
ferent models with MPO in solution [24,25]. We thus expected an
inhibitory effect of immobilized antibodies on the MPO activity,
but the MPO activities measured in the tested samples are calcu-
lated from a calibration curve, in which the reference human MPO
is submitted to the same inhibitory effect of the antibody.
Good conditions for MPO incubation with the primary antibody
were established at 37 ◦C for 2h. Interestingly, the values obtained
after an overnight incubation at 4 ◦C or a 2h incubation at 37 ◦C
were similar (CV<10%): the overnight incubation at 4 ◦C can thus
be used as an alternative condition for the SIEFED technique.
A good sensitivity of the test was obtained with the ﬂuorogenic
substrate Amplex Red,which is transformedduring the peroxidasic
cycle of MPO into the ﬂuorescent resoruﬁn in the presence of H2O2
[12,23].Wesucceeded togreatly increase the sensitivityof the reac-
tion by adding nitrite to the reaction mixture [20]. This increasing
effect canbeﬁrstly explainedbyacooperationofnitrite andAmplex
Red for the turn over of the peroxidasic reaction of MPO. Burner et
al. [26] showed that nitrite is a good substrate to reduce the com-
pound I of MPO provided that a good electron donor is present to
reduce the compound II. Amplex Red could play the role of the sec-
ond electron donor for compound II. But, the oxidation of nitrite by
the compound Imediates nitrogen dioxide, a reactive radicalwhich
can reactwithﬂuorescentprobes [27]. Thus a secondway toexplain
the ampliﬁcation role of nitrite is the reduction of nitrogen dioxide
by Amplex Red allowing both the formation of resoruﬁn and the
recycling of nitrite for the turnover of the peroxidasic cycle.sistently higher MPO activity was measured in samples collected
on heparin and in serum than in samples on EDTA or citrate. The
delay between blood sampling and centrifugation increased the
MPO activity values for all the anticoagulants, but the increase
e/total MPO ratio in plasma of 19 healthy donors (mean± SD) and in 5 plasmas, 5
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as similar for citrate and EDTA and more pronounced for hep-
rin. These results are in agreement with previous studies showing
igher total MPO contents in heparin plasma and serum than in
itrate and EDTA plasma [28,29].
The SIEFED method allows reliable quantiﬁcation of MPO activ-
ty from 0.156 to 10mU/mL, what corresponds to 0.78–50ng/mL
ure MPO. The dilution buffer stabilizes the enzyme during the
ncubation time and freezing–thawing cycles, because BSA and
ween 20 are known to prevent adhesion and aggregation of
roteins [30]. The intra-assay coefﬁcients of variation of the ref-
rence curve do not exceed 8%. The detection limit of the assay
0.080mU/mL) allows an easy measurement of active MPO in
iluted biological ﬂuids. Like for ELISA, the dilution of the sam-
les increases the sensitivity of the test by reducing the interactions
etweenMPOandotherbiomoleculesof the sampleandby improv-
ng the binding of MPO to the primary antibody. The polyclonal
ntibody could also recognize the precursor ofMPO,which is active
n human [31]. The dilutions of 1:10 to 1:20 are adequate for most
f the samples, but we cannot exclude that higher dilutions will be
ecessary for pathological samples.
We calculated the mean normal value of active MPO measured
n EDTA plasmas as 15.1±5.2ng/mL or 3.0±1.0mU/mL, but the
umber of tested normal plasmaswill be increased by further stud-
es. In pathological samples, we measured MPO activities ranging
rom 2.9 to 42.1mU/mL for plasmas, 1.8 to 473.0mU/mL for carotid
xtracts and 2.6 to 50.8mU/mL for BALs with good intra-assay CVs
below 10%) and acceptable inter-assay CVs (below 20%). These
reliminary results indicate that the SIEFED technique will be use-
ul to measure the active MPO in biological ﬂuids or extracts from
atients suffering from inﬂammatory pathologies with neutrophil
ctivation and inﬁltration [6,22,32,33]. In theses pathologies, the
easurement of total MPO by ELISA is often taken as a marker of
eutrophil activation, but we compared the total and active MPO
ontents in samples and found in plasma an active/total MPO ratio
f 0.4±0.1 in healthy donors and a higher but variable ratio of
.5–0.9 inpathological subjects. A still higher variability of this ratio
from 0.2 to 0.9) was observed for carotid extracts and BALs from
athological subjects. These original results suggest an important
ariability of active MPO contents in pathological samples prob-
bly linked to the activation status of neutrophils, the inhibitory
apacity of the ﬂuids towards the enzyme or other disease condi-
ions. The results obtained with the SIEFED technique emphasized
he importance of measuring the active part of MPO, which is the
ealwitness of the oxidant potential of the enzyme that is not taken
nto consideration by a classical ELISA. Indeed, the presence of free
ctiveMPO increases the risk of cytotoxicity, as the enzyme is taken
p by cells or binds on the cell surface with an in situ production
f oxidant species [34,35], which are involved in chlorination and
itration of proteins [2,6], and surely contribute to the pathogen-
sis of the disease [2,6] or to the modulation of the inﬂammation
eaction [36].
In conclusion, the SIEFED technique that we developed for
uman MPO opens news perspectives for the study of patholo-
ies accompanied by the release of active MPO. The SIEFED is a
ethod of choice to measure easily, reliably, quantitatively, and
peciﬁcally the active part of MPO present in biological samples
r tissue extracts. Moreover, SIEFED and ELISA can be used as com-
lementary immunological techniques to determinewith accuracy
[
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the active/total MPO ratio in biological samples, what constitutes a
new prospect in clinical research.
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